Tc 99m sulesomab

Drug Profile

Tc 99m sulesomab

Alternative Names: IMMU-MN3; ImmuRAID MN3 Tc 99m; LeukoScan

Latest Information Update: 15 Jul 2010

Price : $50

At a glance

  • Originator Immunomedics
  • Class Monoclonal antibodies; Monoclonal antibody diagnostics; Radiopharmaceutical diagnostics
  • Mechanism of Action Radionuclide imaging enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Marketed Osteomyelitis

Most Recent Events

  • 17 Jan 2005 Registered for Osteomyelitis diagnosis in Canada (IV)
  • 30 Jun 2003 Data from a media release have been added to the Musculoskeletal Disorders therapeutic trials section
  • 13 Jun 2002 Tc 99m sulesomab has been licensed to Teva-Tuteur in Latin America
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top